Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Financial calendar
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 7, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Latest press releases
Investor Relations Contact
Lucie Larguier, +33 (0)3 88 27 91 00
Key documents
Contact Relations Investisseurs
Lucie Larguier, +33 (0)3 88 27 91 00
Financial information
Key figures
| In € million except share and per share data | 2022 | 2021 | 2020 | 2019 | 2018 |
| Revenue | 10.3 | 17.4 | 9.9 | 13.7 | 42.9 |
| R&D Expense | -32.2 | -32.9 | -27.3 | -31.4 | -27.3 |
| G&A Expense | -7.9 | -7.4 | -6.5 | -7.1 | -7.0 |
| Net income (loss) | -32.8 | -19.5 | -17.2 | -18.8 | 8.0 |
| Net Cash Burn | -22.8 | -10.0 | -17.0 | -20.5 | -24.5 |
| Cash & Cash Equivalents | 26.8 | 49.6 | 26.3 | 43.3 | 16.9 |
| Earnings/Loss per Share (Basic) | -0.33 | -0.21 | -0.21 | -0.23 | 0.13 |
| Earnings/Loss per Share (Diluted) | -0.33 | -0.20 | -0.21 | -0.23 | 0.13 |
| Shares Outstanding | 100,204,071 | 97,771,334 | 83,841,334 | 83,265,464 | 62,275,923 |
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
- 2022: at June 30, 2023
- 2022: at December 31, 2022; at June 30, 2022
- 2021: at December 31, 2021; at June 30, 2021
- 2020: at December 31, 2020; at June 30, 2020
- 2019: at December 31, 2019; at June 30, 2019
- 2018: at December 31, 2018; at June 30, 2018
- 2017: at December 31, 2017; at June 30, 2017
- 2016: at December 31, 2016; at June 30, 2016
Chairman’s report on corporate governance and internal controls
Annual General Meeting information
- May 25, 2022: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 26, 2021: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 27, 2020: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment B) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 100,852,742 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech / CAC Mid 100 |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Bryan Garnier & Co. Ltd | Olga Smolentseva | osmolentseva@bryangarnier.com | +33 (0)1 56 68 75 57 |
| Cantor Fitzgerald | Brandon Folkes | brandon.folkes@cantor.com | +1 212-294-8081 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Life Science Capital LLC | Jacques A. Villefranc | jacques@lifesciadvisors.com | +1 646 597-6997 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Webcasts
- September 20, 2023 - 2023 Half-year results and business update
- May 5, 2023 - New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- March 16, 2023 - 2022 Full-year results and business update
- September 27, 2022 - Transgene R&D Day (Paris, France)
- September 7, 2022 - 2022 Half-year results and business update
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- September 22, 2021 - Half-Year results 2021 & Business Update
- March 16, 2021 - 2021 Full-year results and business update
- March 11, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001 (in French)
- March 10, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001
Financial calendar
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 7, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Investor events
- January 9, 2023 - 26th ODDO BHF Forum – Virtual – January 9 and 10, 2023
- January 9, 2023 - LifeSci Advisors Corporate Access Event – San Francisco, USA – January 9 to 12, 2022
- January 24, 2023 - Invest Securities Biomed Forum – January 24, 2023
- January 27, 2023 - Degroof Petercam’s Virtual Healthcare Conference – January 27, 2023
- February 6, 2023 - BIO CEO & Investor Forum (New York) – February 6 to 9, 2023
Annual General Meeting
Annual General Meeting of May 5, 2023
2023 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 5 May 2023 at 09 am – webcast (live and replay)
Documents
- Notice of the 2022 General Shareholder’s Meeting / BALO (in French)
- Voting formular
- Universal Registration Document 2022
- Information regarding the total number of the outstanding shares and voting rights of the company
- Results of the vote (in French)
